Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More
Xconomy
FEBRUARY 9, 2018
A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. Second, it still hasn’t proven whether the combination helps patients more than its immunotherapy drug nivolumab (Opdivo) used alone. But the results, touted as positive, left more questions than answers.
58 
Let's personalize your content